[go: up one dir, main page]

MX2023006811A - Compuestos novedosos. - Google Patents

Compuestos novedosos.

Info

Publication number
MX2023006811A
MX2023006811A MX2023006811A MX2023006811A MX2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A
Authority
MX
Mexico
Prior art keywords
respect
compounds
properties
new compounds
glp
Prior art date
Application number
MX2023006811A
Other languages
English (en)
Inventor
Stephen Robert Bloom
Original Assignee
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2019588.9A external-priority patent/GB202019588D0/en
Priority claimed from GBGB2110809.7A external-priority patent/GB202110809D0/en
Application filed by Ip2Ipo Innovations Ltd filed Critical Ip2Ipo Innovations Ltd
Publication of MX2023006811A publication Critical patent/MX2023006811A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención proporciona compuestos novedosos que son análogos de hormonas peptídicas y que son útiles en el tratamiento de trastornos tales como la diabetes y la obesidad. Los compuestos de la secuencia general descrita en la especificación poseen un perfil adaptado con respecto a las propiedades de potencia en los receptores de glucagón y GLP-1. Con respecto a las propiedades in vivo, se ha demostrado que la administración de péptidos de ejemplo de la invención, en modelos animales, produce un aumento de la pérdida de peso. Los compuestos preferidos lo consiguen sin reducir significativamente el consumo de alimentos.
MX2023006811A 2020-12-11 2021-12-10 Compuestos novedosos. MX2023006811A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2019588.9A GB202019588D0 (en) 2020-12-11 2020-12-11 Novel Compounds
GBGB2110809.7A GB202110809D0 (en) 2021-07-27 2021-07-27 Novel compounds
PCT/GB2021/053249 WO2022123271A1 (en) 2020-12-11 2021-12-10 Novel compounds

Publications (1)

Publication Number Publication Date
MX2023006811A true MX2023006811A (es) 2023-07-12

Family

ID=79021073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006811A MX2023006811A (es) 2020-12-11 2021-12-10 Compuestos novedosos.

Country Status (10)

Country Link
US (2) US20240336669A1 (es)
EP (1) EP4259646A1 (es)
JP (1) JP2024501467A (es)
KR (1) KR20230125802A (es)
AU (1) AU2021397877A1 (es)
CA (1) CA3199733A1 (es)
GB (2) GB2637108B (es)
IL (1) IL303549A (es)
MX (1) MX2023006811A (es)
WO (1) WO2022123271A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201908424D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
KR20230125802A (ko) 2020-12-11 2023-08-29 아이피2아이피오 이노베이션스 리미티드 신규 화합물
WO2025049610A1 (en) * 2023-08-28 2025-03-06 Shattuck Labs, Inc. Multi-action peptides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
EP1663295A2 (en) * 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
BRPI0608516A2 (pt) * 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
JP2010538069A (ja) * 2007-09-07 2010-12-09 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ エキセンディン−４およびエキセンディン−３の類似体
WO2009143014A1 (en) * 2008-05-23 2009-11-26 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
EP2413955A4 (en) * 2009-04-01 2012-12-26 Amylin Pharmaceuticals Inc N-TERMINAL CONFORMATION RESTRICTED GLP-1 RECEPTOR AGONIST COMPOUNDS
AU2011247452B2 (en) * 2010-04-27 2016-03-17 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
GB201404002D0 (en) 2014-03-06 2014-04-23 Imp Innovations Ltd Novel compounds
CN104211801A (zh) * 2014-07-25 2014-12-17 杭州诺泰制药技术有限公司 一种制备利西拉来的方法
WO2017178829A1 (en) 2016-04-15 2017-10-19 Imperial Innovations Limited Peptide analogues
SG11201903938XA (en) * 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
KR20230125802A (ko) 2020-12-11 2023-08-29 아이피2아이피오 이노베이션스 리미티드 신규 화합물

Also Published As

Publication number Publication date
WO2022123271A1 (en) 2022-06-16
IL303549A (en) 2023-08-01
JP2024501467A (ja) 2024-01-12
EP4259646A1 (en) 2023-10-18
US12497438B2 (en) 2025-12-16
CA3199733A1 (en) 2022-06-16
GB2616205A (en) 2023-08-30
KR20230125802A (ko) 2023-08-29
US20250368710A1 (en) 2025-12-04
AU2021397877A1 (en) 2023-07-06
GB202505837D0 (en) 2025-06-04
GB2637108B (en) 2025-10-15
US20240336669A1 (en) 2024-10-10
GB2637108A (en) 2025-07-09
AU2021397877A9 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
MX2023006811A (es) Compuestos novedosos.
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CO2020014180A2 (es) Derivados de gip y usos de estos
ECSP21030933A (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
MX2016004461A (es) Analogos de glucagon acilados.
CO7400885A2 (es) Análogos de glucagón
MX372841B (es) Análogo acilado del glucagón.
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CL2022000178A1 (es) Análogos de relaxina y métodos para usarlos
PE20151808A1 (es) Peptidos terapeuticos
MX2018014016A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
PE20211417A1 (es) Analogos novedosos de glp-1
ECSP12011593A (es) Análogos de glucagón acilados
CO6551738A2 (es) Anàlogo peptìdico de oxintomodulina
CO6551737A2 (es) Anàlogo peptìdico de oxintomodulina
PE20151770A1 (es) Compuesto peptidico
MX368435B (es) Analogos del glucagon.
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
MX2016006049A (es) Mimeticos de calcitonina para tratar enfermedades y trastornos.
SA522432563B1 (ar) نظير ببتيد أوكسينتو موديولين معالج بأسيل
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
MX2024000757A (es) Variantes recombinantes de proteínas r-espondina y uso de las mismas.
MX2025009969A (es) Compuestos analogos de hormonas peptidicas
AR116803A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta